Retinal ganglion cell complex and visual evoked potentials in levetiracetam treatment

Hazirolan D., Duman M., KESKİN GÜLER S., ÜNEY G., Ornek F.

Cutaneous and Ocular Toxicology, cilt.39, sa.3, ss.237-243, 2020 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 39 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1080/15569527.2020.1778016
  • Dergi Adı: Cutaneous and Ocular Toxicology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, Environment Index, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.237-243
  • Anahtar Kelimeler: Levetiracetam, visual evoked potential, ganglion cell complex layer, retinal nerve fiber layer, optic coherence tomography
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: To examine central macular, RNFL (retinal nerve fibre layer), GCC (ganglion cell complex) thicknesses; and VEPs (visual evoked potential) in epileptic patients using levetiracetam for at least one year. Materials and Methods: Sixteen focal epileptic patients receiving levetiracetam monotherapy and 16 healthy subjects were included in the study. Central macular, RNFL and GCC thicknesses according to spectral domain OCT (optical coherence tomography); and VEPs parameters were compared between patients and healthy subjects. Results: The mean age of patient and control groups were 40 ± 16 and 38 ± 12 years respectively (p ' 0.05). The patient group was on levetiracetam therapy for 64 ± 45 (12–168) months. Central macular thickness was thinner in the patient group (p = 0.008). There was no difference among groups regarding RNFL thicknesses. GCC thicknesses in all quadrants were similar among groups, except the superior quadrant; which was thinner in the patient group (p = 0.03). P100 amplitude in 30 min pattern was lower in the patient group (p = 0.04). N135 latency in 15 min (p = 0.03) and 7 min patterns (p = 0.01) was longer in the patient group. Conclusion: Central macular and GCC thicknesses; and VEP parameters in patients receiving levetiracetam treatment may differ from healthy subjects.